News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma AB – Interim report second quarter 2014

August 28, 2014

PledPharma AB
Interim information

PledPharma AB - Interim report second quarter 2014

Stockholm, 2014-08-28 08:30 CEST (GLOBE NEWSWIRE) -- 
Over 100 patients included in the PLIANT cancer study

“70 patients have so far been treated with the new dosing in the PLIANT study.
Together with the already treated 39 patients according to previous protocol, a
total of over 100 patients have now been treated in Part 2 of the study. " says
CEO Jacques Näsström 

Quarter summary

  -- Net result amounted to SEK -12 674k (-6 048k)
  -- Cash and cash equivalents on June 30 amounted to SEK 47 799k (59 116k)
  -- Cash flow from operating activities amounted to SEK -13 770k (-7 708k)
  -- Result per share amounted to SEK -0.5 (-0.3)

Significant events during April – June

  -- Approval from the DSMB (Drug Safety Monitoring Board) to also include
     Avastin (bevacizumab) patients in Part 2 of the PLIANT study
  -- A rights issue was conducted which generated approximately 20 MSEK 
  -- Patent approved in Hong Kong for the use of PLED-substances in the
     treatment of cancer
  -- Martin Nicklasson was elected to the board of directors

Significant events after the end of the period

  -- Futility analysis in PLIANT study completed and approved by the DSMB
  -- Positive data from patients treated with the FOLFOX in combination with
     bevacizumab in the first part of the PLIANT study

CEO comments

We have now been able to significantly increase the recruitment rate in the
PLIANT study and to date we have included 70 of the 126 patients that need to
be included. 

Additionally, 39 patients were treated according to the previous protocol
(where about one third of the patients received a dose of 10 μmol/kg). This
means that within the PLIANT study's second part, we have up until today
treated at least 109 patients. The results from these first 39 patients will
help us to build up a better dose-response curve and also strengthens the
statistical evaluation together with the other 126 patients. 

Recently the DSMB reported that the futility analysis for the first 30 patients
in the study who have completed four treatment cycles with the chemotherapy
mixture FOLFOX after pretreatment with either PledOx or placebo has been
completed and that no negative impact on the anti-cancer effect of the
chemotherapy was observed. This approval means that the PLIANT trial can
proceed as planned. The safety analysis is important since there has been a
concern that the PledOx drug not only protects healthy cells but also the
cancer cells. The DSMB has therefore had an extra focus on this during the
analysis but no negative impact on the anti-cancer effect of the chemotherapy
has been observed. Additional safety analyzes will be conducted for every 30
patients enrolled that have completed four treatment cycles with chemotherapy.
The next analysis will be preformed in the beginning of September. 

We have now received data from an additional 5 patients in the first part of
the PLIANT study. The data showed that PledOx was well tolerated by these 5
patients who were treated with the antibody Avastin (bevacizumab) in
combination with FOLFOX chemotherapy. In total 11 patients have been treated in
this open part of the study and preliminary analysis of the raw data indicated
that PledOx® reduced the severe chemotherapy-induced side effects. Nine of
these 11 patients underwent at least 6 treatment cycles of FOLFOX and none of
these patients showed any grade 2 or worse neuropathy against an expected
outcome of at least two patients. These data also indicated a reduction of
serious blood-related side effects with the 5 μmol/kg dose of PledOx. 

In summary, I feel that we have now taken a major step forward in our main
study PLIANT and I'm confident that we will keep the goal that all patients
should be included in the study at the end of the year. We now look forward to
an exciting fall for PledPharma. 

For further information, please contact:

Jacques Näsström, CEO

+46 737 13 09 79

Michaela Gertz, CFO

+46 709 26 17 75

About PledPharma

PledPharma is a Swedish pharmaceutical company that develops new therapies for
the treatment of life threatening diseases. The initial objective is to develop
a drug, PledOx®, which reduces severe side-effects associated with
chemotherapy. The current market for supportive cancer care is some USD 10
billion. PledPharma also evaluates an existing medicines possibility to reduce
the damage that occurs on the heart muscle when patients suffer from acute
myocardial infarction. In addition to these projects, the company is also
evaluating opportunities of using our technology platform in additional areas
where there is a significant unmet medical need. PledPharma has the potential
to offer patients valuable and unique treatments for serious life-threatening
diseases where there is an opportunity fast registration in the US through
"breakthrough therapy" designation.  PledPharma (STO:PLED) is listed on NASDAQ
OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For
further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10